Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Follow-Up Questions
Who is the CEO of Acrivon Therapeutics Inc?
Dr. Peter Blume-Jensen is the Chairman of the Board of Acrivon Therapeutics Inc, joining the firm since 2018.
What is the price performance of ACRV stock?
The current price of ACRV is $1.66, it has decreased 0.53% in the last trading day.
What are the primary business themes or industries for Acrivon Therapeutics Inc?
Acrivon Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Acrivon Therapeutics Inc market cap?
Acrivon Therapeutics Inc's current market cap is $52.2M
Is Acrivon Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Acrivon Therapeutics Inc, including 4 strong buy, 9 buy, 2 hold, 0 sell, and 4 strong sell
